HOMEABOUT USCOLOPHONCONTACTPUBLICATIONSLINKS

Non-profit partnerships for pharmaceutical R&D
by
Volker Lehmann
Keywords:  Biotechnology programmes/networks, Private industry, Public institute, Drugs, Vaccine, AIDS, Malaria.
back to the article V. Lehmann: New models for public-private partnerships in drug development

G. Walt & L. Lush: Getting drugs to where they are needed: Global public private partnerships for neglected diseases

B. Levings & P. Kahn: Phase I DNA vaccine trial begins in Nairobi

back

 

Name Donors Finance Private sector partners Current projects Ownership snd patent stipulation
Global TB Alliance GF; RF Total of US$ 40 million Projects and partners are not yet disclosed TB drugs Some ownership of compounds; patents decided upon case-by case.
HIV Vaccine Design and Development Teams (HVDDT) * NIAID/NIH (USA) Total of US$ 70 million for 5 years Advanced BioScience Laboratories (USA); Chiron Corporation (USA); Wyeht Lederle Vaccines and Nutriton (USA) HIV vaccine; 4 vaccine projects; first clinical tests expected in 2002 US laws on publicly funded research (Baye-Dole-Act): The inventor gets the patent, but federal agencies can exert compulsory licencing.
International AIDS Vaccine Initiative GF; RF; other  philantropich institutions; WB; Internaltional development agencies from the UK, Canada, Ireland, the Netherlands Total of US$ 230 million until 2007 AlphaVax (USA); Targeted Genetics (USA); Therion Biologics (USA) 6 HIV vaccine candidates under development; one phase I trial in Kenya Patents go to private partners; IAVI stipulates prices and use of technologies.
Medicine for Malaria Venture (MMV) GF; RF; internationatl devlopment agencies from Switzerland, UK, the Netherlands; WB; WHO; Exxon Mobil (USA) Project funding: US$10 million in 2001; targeted for US$ 15 million in 2002 GlaxoSmithKline (UK); F. Hoffman-La Roche (Switzerland) 3 exporatory and 3 drug discovery projects funded for a total of US$ 4.2 million; 8 discovery and development projects to be added. Private partners receive patents in non-endemic countries and for applications other than malaria. MMV receives patents in disease-endemic countries and for treatment of malaria.
Malaria Vaccine Initatiave (MVI) GF Total of US$ 50 million for 5 years GlaxoSmithKline (UK); Apovia (Germany/USA) Phase I trials in Gambia for one candidate Patent belongs to private partners; if they abandon commercialization, MVI retains back-up development and manufacturing rights.

* Not a Virtual Pharmaceutical Company, but a US government programme to fund vaccine R&D in collaboration with private companies.

Table compiled by the author.


GF Bill & Melinda Gates Foundation http://www.gatesfoundation.org
NIAID/NIH National Institutes of Allergy and Infectious Diseases/
National Institutes of Health
http://www.niaid.nhi.gov
RF The Rockefeller Foundation http://www.rockfound.org
WB World Bank http://www.worldbank.org
WHO World Health Organization http://www.who.int

Global TB Alliance The Global Alliance for TB Drug Development http://www.tballiance.org
HVDDT HIV Vaccine Design and Development Teams
IAVI International AIDS Vaccine Initiative http://www.iavi.org
MMV Medicine for Malaria Venture http://www.malariamedicines.org
MVI Malaria Vaccine Initiative www.malariavaccine.org

TB tuberculosis



Contributions to the Biotechnology and Development Monitor are not covered by any copyright. Exerpts may be translated or reproduced without prior permission (with exception of parts reproduced from third sources), with  acknowledgement of source.

 


back to top
monitor homepage
index of this issue
contact us